Login
$ARWR
$44.25 +$0.04 (0.09%) After hours

$ARWR SEC Filings

Filed On Filing
12 Nov 2026 10-K
12 Nov 2026 8-K: Results of Operations and Financial Condition

Conference Call and Webcast Today, November 12, 2026, at 4:30 p.m. ET

05 Nov 2026 SCHEDULE 13G/A
04 Nov 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

–Existing $400 million facility prepaid at a $68 million discount to the contractual minimum repayment amount

20 Aug 2026 Form 4: Olukotun Adeoye Y, Director

Sold 2,000 shares ($174K)

20 Aug 2026 Form 4: Perry Michael S, Director

Sold 11,600 shares ($1.01M)

18 Aug 2026 144
18 Aug 2026 144
14 Aug 2026 SCHEDULE 13G/A
04 Aug 2026 8-K: Results of Operations and Financial Condition

Conference Call and Webcast Today, August 4, 2026 at 4:30 p.m. ET

04 Aug 2026 10-Q
31 Jul 2026 SCHEDULE 13G/A
27 Jul 2026 SCHEDULE 13G/A
17 Jun 2026 Form 4: Cohen Matthew Gregory, Director

Received 11,882 shares as a grant or award

17 Jun 2026 Form 3: Cohen Matthew Gregory, Director

Holds 0 shares of Common Stock

16 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026.

19 May 2026 144/A
19 May 2026 144/A
19 May 2026 144/A
14 May 2026 Form 4: Lu Hongbo, Director

Sold 2,970 shares ($228K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support